Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

  • ID: 4327552
  • Report
  • 26 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ChironWells GmbH
  • RaQualia Pharma Inc
  • Vitality Biopharma Inc
  • MORE
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (OBD or OIBD) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ChironWells GmbH
  • RaQualia Pharma Inc
  • Vitality Biopharma Inc
  • MORE
Introduction

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development

ChironWells GmbH

RaQualia Pharma Inc

Vitality Biopharma Inc

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Drug Profiles

ORP-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORP-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00433412 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by ChironWells GmbH, H1

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by RaQualia Pharma Inc, H1

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Vitality Biopharma Inc, H1

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects, H1

List of Figures

Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • ChironWells GmbH
  • RaQualia Pharma Inc
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll